According to a recent LinkedIn post from Neuronoff Inc, the company is showcasing multi-site implantable pulse generator (IPG) compatibility for its Injectrode platform. The content indicates that a needle-delivered tripolar Injectrode can connect to standard spinal cord stimulation IPG connectors and selectively stimulate lumbar dorsal root ganglion, peripheral nerve, and sacral targets from a single IPG.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post references fluoroscopic images and a three-month large animal study using a remote-controlled IPG to investigate three interventional pain targets. This suggests Neuronoff is positioning Injectrode as a versatile neuromodulation solution that could address multiple chronic pain indications while leveraging existing SCS-approved IPG hardware.
For investors, this apparent compatibility with standard IPG ecosystems may lower adoption barriers by integrating with installed neuromodulation infrastructure rather than requiring proprietary generators. If validated in human studies and accepted by clinicians, this approach could expand the addressable market across SCS, peripheral nerve stimulation, sacral neuromodulation, and potentially other segments such as vagus nerve stimulation.
The linked press release, referenced but not detailed in the post, appears intended to formalize these preclinical findings and emphasize ecosystem and patient-access benefits. While clinical, regulatory, and reimbursement milestones remain key uncertainties, the development described suggests Neuronoff is advancing toward a platform strategy that could enhance its competitive position in the chronic pain neuromodulation field.